Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.
Bay 12-8039, a new 8-methoxy quinolone, was compared with other agents for activity against clinically relevant anaerobes. Bay 12-8039 inhibited 91 and 96% of the 410 test isolates at 2 and 4 micrograms/ml, respectively. Bay 12-8039 had activity comparable to that metronidazole and overall was at least 16-fold more active than ciprofloxacin, ofloxacin, and cefoxitin, 32-fold more active than cefotetan, and at least 128-fold more active than penicillin G.
Aldridge
K E
KE
Department of Medicine, Louisiana State University Medical Center, New Orleans 70112, USA.
Ashcraft
D S
DS
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D001424:Bacterial Infections / Q000382:microbiology; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D011804:Quinolines; D015363:Quinolones / Q000494:pharmacology*
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D015363:Quinolones; D000077266:Moxifloxacin